Video webcast now available here

TAMPA, FL and LONDON – August 27, 2026 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that it participated in the Virtual Investor “Why Now” on-demand conference.

During the webcast, Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, presented the Company’s investment thesis, highlighting why he believes now is a pivotal time for Akari. The discussion highlights the rapidly evolving ADC landscape, increasing industry demand for differentiated payload technologies, and Akari’s proprietary PH1 RNA splicing payload platform, which is designed to address limitations associated with conventional ADC payloads.

The video webcast is now accessible for on-demand viewing here.

JTC Team and Virtual Investor Co. are paid consultants to Akari Therapeutics, Plc. JTC Team and Virtual Investor Co. are investor relations and corporate communications firms. Any content included in this release shall not be construed as an offer to purchase securities of Akari Therapeutics, Plc. Interested parties are responsible for conducting their own due diligence and are encouraged to review the Company’s website and the SEC website for the latest information and filings on the Company.

About Akari Therapeutics

Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use microtubule inhibitors and DNA-damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune systems to drive robust and durable activity. In preclinical studies, AKTX-101 has been shown to have significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, ARV7, FGFR3 fusions, and others. The Company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by mid-2027. Akari is also developing AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen broadly expressed across multiple solid tumors. AKTX-102 is designed to leverage Akari’s proprietary PH1 spliceosome-modulating payload and a novel antibody construct to enable differentiated tumor cell killing and immune activation.

For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding the ability of the Company to advance its product candidates for the treatment of cancer and the timing of commencement of a Phase I clinical trial. These statements are based on the Company’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the Company’s need for additional capital; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the business; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of the Company’s programs or product candidates; risks related to any loss of the Company’s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company’s product candidates, including as a result of potential tariffs; the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company’s product candidates; risks related to competition for the Company’s product candidates; and the Company’s ability to successfully develop or commercialize its product candidates. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release except as required by law.

Investor Relations Contact

JTC Team, LLC

Jenene Thomas 

908-824-0775

AKTX@jtcir.com

Company invited to present alongside global pharmaceutical, biotechnology and industry leaders at five high-profile U.S. and China conferences in September

CEO Abizer Gaslightwala to deliver keynote and featured presentations on next-generation ADC payload innovation and partnerships/collaborations

TAMPA, FL and LONDON – September 08, 2026 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that the Company has been selected to participate in five prominent oncology, ADC and healthcare industry and investor conferences in the United States and China during September 2026.

These speaking engagements position Akari’s proprietary PH1 ADC payload technology in front of leading global pharmaceutical and biotechnology companies focused on ADCs, potential strategic partners, and healthcare investors at a time when the industry is increasingly focused on novel payloads and next-generation ADC technologies.

Through these various presentations and expert panels, Akari expects to highlight the potential of its PH1 platform to enable differentiated ADCs, discuss emerging strategies for improving ADC efficacy and safety, and explore opportunities for global R&D collaboration, platform partnerships, and its pipeline expansion.

“We believe being selected to actively participate in these conferences and discussions reflects growing interest in novel ADC payload technologies and key unmet needs around ADC therapy sequencing,” said Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics. “These key conferences in September give us an exceptional opportunity to put the PH1 ADC payload and Akari’s next-generation ADC strategy in front of potential partners across pharma and biotechnology companies and strategic healthcare investors. We believe the next wave of ADC innovation will be driven in significant part by differentiated payloads, and we are excited to showcase the potential and opportunity for Akari’s ADC payload targeting RNA splicing. As we advance AKTX-101 toward the clinic, these forums also provide an important opportunity to deepen strategic relationships and demonstrate the broader potential of our PH1 payload platform.”

Oncology & Immunology Innovation Partnering & Licensing Summit

Dates: September 9–10, 2026

Location: Boston, Massachusetts

Panel: Thursday, September 10, 2026, at 8:30 AM ET

Panel Title: Reflecting on the First Attempts with Novel Payloads & What We Are Doing Differently Now

Session: Novel Payloads & Combinations as the New Value Driver in ADCs

Participant: Abizer Gaslightwala, President and Chief Executive Officer, Akari Therapeutics

Mr. Gaslightwala will participate in a discussion focused on the evolution of novel ADC payloads and how emerging technologies could help address limitations associated with current ADCs. The session places Akari directly within a broader industry conversation around novel payloads as potential drivers of the next generation of ADC innovation.

H.C. Wainwright 28th Annual Global Investment Conference

Date: Tuesday, September 15, 2026

Time: 9:00 AM EST

Webcast: Access it Here (https://journey.ct.events/view/173db417-75e1-47c0-95be-d440d2a5b96b)

Investors interested in meeting with Akari management during the conference are encouraged to contact their H.C. Wainwright representative to request a meeting.

BioCon China 2026

Dates: September 15–16, 2026

Location: Shanghai, China

Keynote Presentation: Tuesday, September 15, 2026, from 10:45–11:15 AM (CST)

Presentation Title:

From Big Pharma to Biotech: Differentiated Value of Next-Gen ADCs and China Collaboration Opportunities

Participant: Abizer Gaslightwala, President and Chief Executive Officer, Akari Therapeutics

In addition to the keynote presentation, Mr. Gaslightwala will participate in a speaker panel titled, Opportunities, Partnership Options & Critical Success Factors for Global Collaboration of Chinese‑Innovated Assets: A Multinational Pharma Perspective, focused on the evolving value of differentiated ADC technologies and opportunities for collaboration between global biotechnology companies and the Chinese biopharmaceutical industry.

2026 Global XDC Innovation Conference

Dates: September 17–19, 2026

Location: WuXi, China

Presentation: Saturday, September 19, 2026,

Presentation Title: Novel ADC Payloads Designed to Target RNA Splicing to Drive Differentiated Efficacy and Safety and New Options for ADC Therapy Sequencing

Session: Session IV – XDC New Modalities: BsADC, Dual-Payload ADC, AOC, and Beyond

Participant: Abizer Gaslightwala, President and Chief Executive Officer, Akari Therapeutics

At the Global XDC Innovation Conference, Akari will specifically showcase its approach to developing ADC payloads designed to target RNA splicing and the potential implications for efficacy, safety and therapeutic sequencing. The presentation will position PH1 within the emerging landscape of next-generation ADC technologies being developed.

5th Annual ROTH Healthcare Opportunities Conference

Date: September 29, 2026

Location: New York, New York

Format: Investor meetings

Akari will conclude its September conference schedule at the 5th Annual ROTH Healthcare Opportunities Conference, where management expects to meet with healthcare investors and discuss the Company’s PH1 platform, advancement of AKTX-101 and broader ADC development strategy.

Investors interested in meeting with Akari management during the conference are encouraged to contact their ROTH representative to request a meeting.

Advancing a Differentiated Approach to the Next Generation of ADCs

Akari’s participation across these conferences comes as the Company advances AKTX-101, its lead Trop2-targeting ADC, through IND-enabling development toward a planned first-in-human clinical trial by mid-2027.

Unlike ADCs utilizing traditional microtubule inhibitor or DNA-damaging payloads, Akari’s proprietary PH1 payload is designed to target RNA splicing, providing a differentiated mechanism intended to induce cancer cell death while activating both innate and adaptive immune responses.

Beyond AKTX-101, Akari is developing AKTX-102, targeting CEACAM5, and is exploring the broader potential of its PH1 technology across next-generation ADC architectures and development strategies.

About Akari Therapeutics

Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use microtubule inhibitors and DNA-damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune systems to drive robust and durable activity. In preclinical studies, AKTX-101 has been shown to have significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, ARV7, FGFR3 fusions, and others. The Company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by mid-2027. Akari is also developing AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen broadly expressed across multiple solid tumors. AKTX-102 is designed to leverage Akari’s proprietary PH1 spliceosome-modulating payload and a novel antibody construct to enable differentiated tumor cell killing and immune activation.

For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding the ability of the Company to advance its product candidates for the treatment of cancer and the timing of a filing of an IND and commencement of a Phase I clinical trial. These statements are based on the Company’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific.

Patent filing covers PH1 payload’s unique ability to disrupt multiple cancer-driving pathways in addition to its overall cytotoxic mechanism

Expands intellectual property portfolio supporting Akari’s novel payload and ADC platform

TAMPA, FL and LONDON – October 1, 2026 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing disrupting payload, today announced the filing of PCT/US2026/45955, expanding the Company’s growing intellectual property portfolio around its novel splicing-modulating payload, PH1 and PH1-based ADCs.

Alternative splicing enables cells to generate different proteins from a single gene. Cancer cells can exploit this process to produce protein variants called ‘isoforms’ that support tumor growth, proliferation and survival and promote resistance to therapy. This PCT filing expands Akari’s current patent portfolio relating to its proprietary Thailanstatin payload ADCs and the payload’s ability to disrupt alternatively spliced protein isoforms that many cancers use to survive, proliferate and spread. Accordingly, Akari’s payload PH1 uses a differentiated approach compared with traditional ADC payloads that primarily rely on tubulin inhibition (i.e., vedotin) or DNA damage as (i.e., topoisomerase I Inhibitors) mechanisms of action.

The new PCT application includes claims relating to PH1’s modulation of alternative splicing involving multiple genes associated with tumor progression, including pathways involved in:

- Inhibiting Angiogenesis: PH1 altered VEGF-A splicing, shifting cancer cells from a VEGF-A isoform with the ability to supply tumors with blood vessels bringing in nutrients and oxygen (pro-angiogenic) toward the VEGF-165b isoform that prevented blood vessel recruitment to tumors (anti-angiogenic). This switch may disrupt the ability of tumors to recruit the blood vessels necessary to support their growth and spread.

- Facilitating programmed cell death of the tumor: Cancer cells produce soluble versions of the death receptor FAS to prevent immune cells expressing the FAS ligand from recognizing the cancer cell and killing it. PH1 altered the splicing of FAS to a version that would be anchored on cell surfaces (transmembrane isoform) making the cancer cells susceptible to immune cell-mediated cell death.

- Disrupting hormone and oncogenic signaling in prostate cancer: In prostate cancer cells, PH1 demonstrated reductions in both wild-type androgen receptor (WT-AR) and the oncogenic splice variant AR-V7. WT-AR plays an important role in hormone-dependent prostate cancer, while AR-V7 is a signaling oncogene that drives tumor growth in metastatic castration-resistant prostate cancer (after hormone ablation therapy fails).

Together, these collective findings further demonstrate the versatility of PH1’s mechanism of action and its potential to disrupt different alternative splicing pathways that different cancers rely upon for survival, growth and metastasis.

Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, commented, “This PCT filing represents another important expansion of our intellectual property portfolio and further demonstrates the differentiated potential of PH1 as a novel ADC payload with unique properties vs. current ADC payloads. These claims illustrate PH1’s potential to impact multiple fundamental mechanisms that cancer tumors use to survive and spread, including angiogenesis, oncogene signaling and avoiding programmed cell death. We believe the breadth of this biology further supports the potential of PH1 as a platform payload for the development of differentiated ADCs across multiple tumor targets and cancer types. As we continue to expand our understanding of PH1, we are building an increasingly robust intellectual property foundation for our novel PH1 payload and ADC portfolio.”

About Akari Therapeutics

Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use microtubule inhibitors and DNA-damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune systems to drive robust and durable activity. In preclinical studies, AKTX-101 has been shown to have significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, AR-V7, FGFR3 fusions, and others. The Company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by mid-2027. Akari is also developing AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen broadly expressed across multiple solid tumors. AKTX-102 is designed to leverage Akari’s proprietary PH1 spliceosome-modulating payload and a novel antibody construct to enable differentiated tumor cell killing and immune activation.

For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding the potential characteristics and therapeutic applications of PH1 and PH1-based ADCs, the ability of the Company to advance its product candidates for the treatment of cancer and the timing of a filing of an IND and commencement of a Phase I clinical trial. These statements are based on the Company’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the Company’s need for additional capital; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the business; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of the Company’s programs or product candidates; risks related to any loss of the Company’s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company’s product candidates, including as a result of potential tariffs; the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company’s product candidates; risks related to competition for the Company’s product candidates; and the Company’s ability to successfully develop or commercialize its product candidates. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov.

Mr. Vat-Ho’s appointment adds more than 20 years of oncology, biopharma and capital markets experience, including senior roles in transactions totaling more than $25 billion in aggregate value

Mr. Vat-Ho brings highly relevant ADC payload partnering experience, including recently executed collaborations with Exelixis and BioNTech

TAMPA, FL and LONDON – October 13, 2026 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing disrupting payload, today announced the appointment of Vatnak Vat-Ho as Chief Business Officer, strengthening the Company’s leadership team with an accomplished oncology business development executive whose experience spans major biopharmaceutical transactions, ADC payload collaborations, capital markets and commercial strategy.

Mr. Vat-Ho brings more than 20 years of experience across oncology business development, biopharmaceutical strategy, equity research and healthcare investing. Throughout his career, he has led or held senior transaction roles in deals totaling more than $25 billion in aggregate value, including transactions and collaborations involving Pfizer, Exelixis, BioNTech, Merck KGaA, Roivant and Roche/Genentech.

Importantly for Akari, Mr. Vat-Ho brings direct and recent experience creating strategic collaborations in oncology, including novel ADC payload technology. Most recently, as Chief Business Officer of Ryvu Therapeutics, he originated and closed a collaboration with Exelixis involving a novel ADC payload, as well as a multi-target immuno-oncology research collaboration with BioNTech.

At Akari, Mr. Vat-Ho will lead corporate and business development, including corporate strategy, partnering and licensing, and investor engagement, as the Company advances its lead TROP2-targeted ADC, AKTX-101, toward the clinic and continues to develop the broader potential of its proprietary PH1 spliceosome-modulating payload platform.

“Vatnak is joining Akari at an important point in our evolution, and the relevance of his experience to our strategy is exceptional,” said Abizer Gaslightwala, Chief Executive Officer of Akari Therapeutics. “He has spent his career at the intersection of oncology innovation, strategic transactions and capital markets, and, importantly, he has recent direct experience structuring collaborations around novel ADC payload technology with leading oncology companies. As we advance AKTX-101 toward the clinic and continue to demonstrate the potential breadth of PH1, we believe there is a significant opportunity to create value not only through our wholly owned pipeline, but also through strategic partnerships that can expand the reach and application of our technology. Vatnak gives us additional leadership, relationships and transaction experience to pursue that opportunity with focus and discipline.”

“The ADC field is increasingly recognizing that the payload can be one of the most important drivers of differentiation and value, and I believe Akari has built something particularly compelling with PH1,” said Mr. Vat-Ho. “The combination of a differentiated mechanism of action, encouraging preclinical activity, potential immune activation and applicability across multiple tumor targets creates several potential avenues for value creation. I am excited to join Akari at this stage and work with Abizer and the team to advance AKTX-101, expand the strategic reach of the PH1 platform and pursue partnerships that can accelerate and broaden the development of this technology.”

About Vatnak Vat-Ho

Mr. Vat-Ho brings more than 20 years of experience spanning oncology business development, biopharmaceutical strategy, equity research and healthcare investing. Over his career, he has led or held senior transaction roles in deals totaling more than $25 billion in aggregate value, combining leadership of collaborations with major biopharmaceutical companies with an understanding of the clinical, commercial and financial factors that shape partnering and investment decisions.

Most recently, Mr. Vat-Ho served as Chief Business Officer and a member of the Management Board of Ryvu Therapeutics, where he originated and closed the company’s collaboration with Exelixis on a novel ADC payload, as well as its multi-target immuno-oncology research collaboration with BioNTech. At Ryvu, he also oversaw partnering/BD, U.S. investor relations, commercial development and alliance management. Previously, as Vice President, Business Development at Affimed, he originated and closed a multi-target license and discovery collaboration with Roivant and served as alliance manager for the company’s partnerships including Roche/Genentech.

Prior to that, Mr. Vat-Ho spent eight years at Pfizer Oncology in business development and commercial development, rising to Senior Director and Team Lead, Strategy, Business Development & Alliances. He worked on transactions including the $14 billion acquisition of Medivation, the $850 million upfront avelumab collaboration with Merck KGaA, Darmstadt, Germany, and several strategic financing and out-licensing transactions. He began his career in equity research and healthcare investing at firms including BMO Capital Markets and Broadfin Capital, building a foundation in valuation, capital markets and investor engagement.

Mr. Vat-Ho holds an A.B. in Biology from Harvard University and an M.B.A. from New York University’s Leonard N. Stern School of Business.

About Akari Therapeutics

Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use microtubule inhibitors and DNA-damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune systems to drive robust and durable activity. In preclinical studies, AKTX-101 has been shown to have significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, AR-V7, FGFR3 fusions, and others. The Company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by mid-2027. Akari is also developing AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen broadly expressed across multiple solid tumors. AKTX-102 is designed to leverage Akari’s proprietary PH1 spliceosome-modulating payload and a novel antibody construct to enable differentiated tumor cell killing and immune activation.

For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding the ability of the Company to advance its product candidates for the treatment of cancer and the timing of a filing of an IND and commencement of a Phase I clinical trial. These statements are based on the Company’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements.

CEO Abizer Gaslightwala discusses Akari’s novel PH1 payload strategy and execution priorities supporting AKTX-101’s advancement toward planned Phase 1 clinical development in mid-2027

Recent deal activity and emerging clinical data highlighting limitations of current ADC sequencing reinforce the increasing demand for novel ADC payloads

Access the Akari CEO Corner here

TAMPA, FL and LONDON – October 15, 2026 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing disrupting payload, today released a new CEO Corner segment featuring President and Chief Executive Officer Abizer Gaslightwala discussing the Company’s differentiated ADC payload strategy, recent external validation and the execution priorities supporting AKTX-101’s advancement toward planned Phase 1 clinical development in mid-2027.

At the center of the discussion is Akari’s belief that ADC payload differentiation will become increasingly important as more cancer patients receive ADCs as front-line therapies and develop resistance to the current ADC payload classes leaving limited subsequent therapy options. Mr. Gaslightwala discusses emerging clinical data presented at major medical conferences that sequential treatment of ADCs utilizing the same payload class do not provide benefit after treatment relapse. This is a significant growing unmet need and is an exclusive opportunity for Akari with its novel ADC payload that current and most future ADCs will not be able to access.

Akari is pursuing this exclusive opportunity using its PH1 payload, a novel spliceosome-modulating payload, which is designed to disrupt RNA splicing in cancer cells through a mechanism distinct from commonly used ADC payload classes.

Mr. Gaslightwala also describes recent external engagements and presentations at partnering and industry conferences in the US and China, where there was significant interest in Akari’s ADC payload and its differentiated approach.

“It was important for us to gauge interest and excitement in our novel payload technology and its application to ADC therapies in areas of growing unmet needs like ADC refractory patients, and I left the conferences even more convicted in our technology, strategy, and execution as a company,” said Mr. Gaslightwala. “Across recent partner discussions and industry engagement, our novel PH1 payload generated meaningful interest and reinforced our belief that differentiated payloads can play an increasingly important role as ADC therapies continue to evolve.”

Mr. Gaslightwala also points to recent industry transactions involving novel ADC payload technologies, including Novartis’s agreement to acquire Myricx Bio and Genentech’s collaboration with DualityBio, as additional evidence of strategic interest by Big Pharma companies in acquiring and developing next-generation payload approaches.

With this backdrop, Akari’s focus is now on execution.

The Company continues to advance AKTX-101 through IND-enabling toxicology and safety studies, large-scale GMP manufacturing, and Phase 1 planning, with the goal of initiating clinical development in mid-2027. In parallel, Akari is also continuing discussions with potential strategic partners around PH1 and the broader potential of its payload platform to create a broader pipeline of ADCs using this novel technology

“Our focus now is execution,” said Mr. Gaslightwala. “We are advancing the work required to move AKTX-101 into the clinic while continuing to explore the broader potential of PH1. We believe successful execution could create multiple opportunities for value creation through AKTX-101, potential licensing of our payload technology, and new concepts such as dual-payload approaches based on PH1.”

“We believe Akari has built a differentiated scientific foundation,” Mr. Gaslightwala added. “The next step is to translate that foundation through disciplined execution and demonstrate the potential of this technology in the clinic.”

The CEO Corner segment is now available here.

About Akari Therapeutics

Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use microtubule inhibitors and DNA-damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune systems to drive robust and durable activity. In preclinical studies, AKTX-101 has been shown to have significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, AR-V7, FGFR3 fusions, and others. The Company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by mid-2027. Akari is also developing AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen broadly expressed across multiple solid tumors. AKTX-102 is designed to leverage Akari’s proprietary PH1 spliceosome-modulating payload and a novel antibody construct to enable differentiated tumor cell killing and immune activation.

For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding the potential characteristics and therapeutic applications of PH1 and PH1-based ADCs, the ability of the Company to advance its product candidates for the treatment of cancer and the timing of a filing of an IND and commencement of a Phase I clinical trial. These statements are based on the Company’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the Company’s need for additional capital; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the business; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of the Company’s programs or product candidates; risks related to any loss of the Company’s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company’s product candidates, including as a result of potential tariffs; the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company’s product candidates; risks related to competition for the Company’s product candidates; and the Company’s ability to successfully develop or commercialize its product candidates. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC, copies of which may be obtained from the SEC’s website at www.sec.

IGZ Automation GmbH

SLC für SAP EWM ist der Leitstand zur operativen Überwachung von Lagerprozessen. Individuell konfigurierbare Dashboards stellen relevante KPIs und Status übersichtlich dar. KI-Funktionen analysieren laufend die aktuellen Gegebenheiten, erkennen Anomalien, prognostizieren Engpässe und liefern Handlungsempfehlungen. Zudem erkennen sie repetitive Aufgaben und planen dazu KI-Agenten ein. Das führt zu einer deutlichen Entlastung des Leitstandpersonals.

SLC for SAP EWM is the control station for operational monitoring of warehouse processes. Individually configurable dashboards clearly display relevant KPIs and statuses. AI functions continuously analyze current conditions, detect anomalies, predict bottlenecks, and provide recommendations for action. They also identify repetitive tasks and schedule AI agents to perform them. This significantly reduces the workload for control room personnel.

GEBHARDT Intralogistics Group

GEBHARDT Versastore® eröffnet neue Möglichkeiten für Lager- und Produktionsprozesse. Tablare werden hochdicht und platzsparend in einer blocklagerähnlichen Struktur organisiert und können direkt von Arbeitsplätzen im Lager oder in der Produktion bedient werden. Die flexibel an die Ladungshöhe anpassbaren Tablare machen Versastore® zur idealen Lösung für Unternehmen, die Werkstücke effizient lagern, direkt bearbeiten und in Produktionsprozesse integrieren möchten.

The GEBHARDT Versastore® offers innovative solutions for storage and production processes. It features a high-density, space-saving shelving system that resembles block storage. This system allows for direct operation from warehouse or production workstations. The trays can be easily adjusted to accommodate various load heights, making Versastore® the perfect choice for companies looking to store workpieces efficiently, process them on-site, and integrate them seamlessly into their production workflows.

Daifuku Co., Ltd.

Der Sorting Transfer Robot M (SOTR M) verbindet den stetigen Materialfluss eines stationären Förderbands mit der Flexibilität, Skalierbarkeit und schnellen Konfigurierbarkeit mobiler Roboter. Dieser hybride Ansatz schafft eine neue Klasse von Transport- und Sortiersystemen für Behälter und andere kleine Ladungen. Konzipiert für Hochleistungsanforderungen E-Commerce-, Lebensmittel-, B2C-Fulfillment- und Fabrikumgebungen, ermöglicht SOTR M, schneller zu reagieren und intelligenter zu skalieren.

The Sorting Transfer Robot M (SOTR M) combines the steady material flow of a conveyor with the flexibility, scalability, and rapid reconfigurability of mobile robots. This hybrid approach creates a new class of transport and sorting systems for totes and other small loads.

Designed for fast moving ecommerce, grocery, B2C fulfillment, and factory automation environments, the SOTR M empowers operations to react faster and scale smarter.

LIS Logistische Informationssysteme GmbH

Wir erweitern unser WMS LIS Warehouse Management System (LWM) um eine KI-gestützte Assistenzfunktion, die den Zugriff auf Lagerdaten grundlegend vereinfacht. Anwenderinnen und Anwender können Bestandsinformationen, Artikelbewegungen, Auftragsdaten sowie Auswertungen direkt in natürlicher Sprache abfragen, per Texteingabe oder Sprachsteuerung. Statt sich durch komplexe Menüstrukturen zu navigieren, erhalten sie kontextbezogene Antworten in Echtzeit.

We are expanding our WMS LIS Warehouse Management System (LWM) with an AI-supported assistance function that fundamentally simplifies access to warehouse data. Users can query inventory information, item movements, order data, and evaluations directly in natural language, either via text input or voice control. Instead of navigating through complex menu structures, they receive context-related answers in real time.

HPC Aktiengesellschaft

Der Mobile Builder ist eine SAP-native Low-Code-Plattform zur schnellen Digitalisierung von Prozessen in Logistik, Produktion und Instandhaltung. SAP-Fiori-Apps entstehen direkt im SAP-System – ohne Middleware, externe Plattformen oder zusätzliche Schnittstellen. Mit Drag-and-Drop, integrierter Laufzeit und KI-Unterstützung werden klickoptimierte Anwendungen in Tagen statt Wochen erstellt. Rollen, Berechtigungen und Datenmodelle werden automatisch übernommen.

Mobile Builder is an SAP-native low-code platform for rapidly digitizing processes in logistics, production, and maintenance. SAP Fiori apps are created directly in the SAP system - without middleware, external platforms, or additional interfaces. With drag-and-drop functionality, integrated runtime, and AI support, click-optimized applications can be created in days instead of weeks. Roles, authorizations, and data models are automatically transferred.